Literature DB >> 2013555

Stimulation of human arterial smooth muscle cell chondroitin sulfate proteoglycan synthesis by transforming growth factor-beta.

J K Chen1, H Hoshi, W L McKeehan.   

Abstract

Human platelet-derived transforming growth factor-beta (TGF-beta) is a cell-type specific promotor of proteoglycan synthesis in human adult arterial cells. Cultured human adult arterial smooth muscle cells synthesized chondroitin sulfate, dermatan sulfate, and heparan sulfate proteoglycans, and the percent composition of these three proteoglycan subclasses varied to some extent from cell strain to cell strain. However, TGF-beta consistently stimulated the synthesis of chondroitin sulfate proteoglycan. Both chondroitin 4- and chondroitin 6-sulfate were stimulated by TGF-beta to the same extent. TGF-beta had no stimulatory effect on either class of [35S]sulfate-labeled proteoglycans which appeared in an approximately 1:1 and 2:1 ratio of heparan sulfate to dermatan sulfate of the medium and cell layers, respectively, of arterial endothelial cells. Human adult arterial endothelial cells synthesized little or no chondroitin sulfate proteoglycan. Pulsechase labeling revealed that the appearance of smooth muscle cell proteoglycans into the medium over a 36-h period equaled the disappearance of labeled proteoglycans from the cell layer, independent of TGF-beta. Inhibitors of RNA synthesis blocked TGF-beta-stimulated proteoglycan synthesis in the smooth muscle cells. The incorporation of [35S]methionine into chondroitin sulfate proteoglycan core proteins was stimulated by TGF-beta. Taken together, the results presented indicate that TGF-beta stimulates chondroitin sulfate proteoglycan synthesis in human adult arterial smooth muscle cells by promoting the core protein synthesis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2013555     DOI: 10.1007/bf02630888

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol        ISSN: 0883-8364


  38 in total

1.  Isolation and characterization of different molecular and chromatographic forms of heparin-binding growth factor 1 from bovine brain.

Authors:  W L McKeehan; J W Crabb
Journal:  Anal Biochem       Date:  1987-08-01       Impact factor: 3.365

2.  Sulfated glycosaminoglycans synthesized by human smooth muscle cells isolated from different organs.

Authors:  P A Mourão; M R Luz; R Borojevic
Journal:  Biochim Biophys Acta       Date:  1986-05-02

3.  Acid mucosubstances underlying lipid deposits in ageing tendons and atherosclerotic arteries.

Authors:  C W Adams; O B Bayliss
Journal:  Atherosclerosis       Date:  1973 Sep-Oct       Impact factor: 5.162

4.  Role of lipoproteins in growth of human adult arterial endothelial and smooth muscle cells in low lipoprotein-deficient serum.

Authors:  J K Chen; H Hoshi; D B McClure; W L McKeehan
Journal:  J Cell Physiol       Date:  1986-11       Impact factor: 6.384

5.  Serum contains a platelet-derived transforming growth factor.

Authors:  C B Childs; J A Proper; R F Tucker; H L Moses
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

6.  Calcium, magnesium, and serum factors in multiplication of normal and transformed human lung fibroblasts.

Authors:  W L McKeehan; K A McKeehan
Journal:  In Vitro       Date:  1980-06

7.  Artery wall derived proteoglycan-plasma lipoprotein interaction: lipoprotein binding properties of extracted proteoglycans.

Authors:  R H Steele; W D Wagner; H A Rowe; I J Edwards
Journal:  Atherosclerosis       Date:  1987-05       Impact factor: 5.162

8.  Isolation and preliminary characterization of proteoglycans dissociatively extracted from human aorta.

Authors:  B G Salisbury; W D Wagner
Journal:  J Biol Chem       Date:  1981-08-10       Impact factor: 5.157

9.  A method to evaluate the biosynthesis of glycosaminoglycans by the aorta of Cynomolgus monkey.

Authors:  P Mozzicato; B Faris; W Hollander; C Franzblau; K Schmid
Journal:  Atherosclerosis       Date:  1982-12       Impact factor: 5.162

10.  Lipoprotein-hyaluronate associations in human aorta fibrous plaque lesions.

Authors:  S R Srinivasan; K Yost; B Radhakrishnamurthy; E R Dalferes; G S Berenson
Journal:  Atherosclerosis       Date:  1980-05       Impact factor: 5.162

View more
  8 in total

1.  Selective deposits of versican in the extracellular matrix of restenotic lesions from human peripheral arteries.

Authors:  T N Wight; S Lara; R Riessen; R Le Baron; J Isner
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

Review 2.  The response-to-retention hypothesis of early atherogenesis.

Authors:  K J Williams; I Tabas
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-05       Impact factor: 8.311

Review 3.  Rous-Whipple Award Lecture. Atherosclerosis: a defense mechanism gone awry.

Authors:  R Ross
Journal:  Am J Pathol       Date:  1993-10       Impact factor: 4.307

Review 4.  Cytokines and proteoglycans.

Authors:  J J Nietfeld
Journal:  Experientia       Date:  1993-05-15

5.  Staurosporine induces chondrogenesis of chick embryo wing bud mesenchyme in monolayer cultures through canonical and non-canonical TGF-β pathways.

Authors:  Hyoin Kim; Kyungmin Kei; Jong Kyung Sonn
Journal:  In Vitro Cell Dev Biol Anim       Date:  2015-10-01       Impact factor: 2.416

6.  Alteration of glycosaminoglycans induced by cadmium in cultured vascular smooth muscle cells.

Authors:  T Kaji; S Ohkawara; M Inada; C Yamamoto; M Sakamoto; H Kozuka
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

7.  Liposomal Aerosols of Nitric Oxide (NO) Donor as a Long-Acting Substitute for the Ultra-Short-Acting Inhaled NO in the Treatment of PAH.

Authors:  Kamrun Nahar; Jahidur Rashid; Shahriar Absar; Fahad I Al-Saikhan; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2016-04-05       Impact factor: 4.200

8.  Peptide-coated liposomal fasudil enhances site specific vasodilation in pulmonary arterial hypertension.

Authors:  Kamrun Nahar; Shahriar Absar; Nilesh Gupta; Venkata Ramana Kotamraju; Ivan F McMurtry; Masahiko Oka; Masanobu Komatsu; Eva Nozik-Grayck; Fakhrul Ahsan
Journal:  Mol Pharm       Date:  2014-11-04       Impact factor: 4.939

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.